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Abstract 
Background: IBD patients are sometimes first diagnosed with IBS which may be construed 
as a misdiagnosis.  
Objective: To determine if this occurs more than expected by chance. 
Methods: A case-control study nested in the General Practice Research database. We 
selected incident cases of IBD and up to 10 matched controls for each.  We assessed the 
proportions with IBS recorded prior to the IBD diagnosis and variation by age, sex, and 
calendar time. We compared proportions affected in fixed time periods and conducted 
conditional logistic regression to derive odds ratios. 
Results: The 20,193 cases, were 3 times as likely as controls to have a prior record of IBS. 
15% of IBD cases and 5% of controls had IBS coded before diagnosis with 11% having a 
code for IBS over 1 year before IBD (c.f. 5% of controls) and 6% over 5 years earlier (c.f. 
3%). These figures roughly doubled if typical antispasmodic therapies were assumed to 
represent IBS diagnoses. 
Conclusion: If excess IBS diagnoses represent misdiagnoses of IBD, our results suggest 
that about 10% of IBD patients are misdiagnosed and in 3% of cases this may persist for 5 
or more years. 
INTRODUCTION 
 
Though it is easy to find case reports of the delayed diagnosis of Inflammatory Bowel 
Disease (IBD) and in particular of Crohn’s disease, and even to find statements that this is 
common, evidence as to how common is limited. The evidence available is primarily from 
small or dated studies and often individual case series within a single institution. There is 
however one relatively recent, and high quality United Kingdom (UK) wide study of childhood 
IBD indicating that this is a widespread problem, with symptoms present for in excess of a 
year in 1/5th of cases1. For evidence of the rate of diagnostic delay in adults based on 
similarly robust population based data over a large UK population we must go back to 
Northern Ireland in the 1960s and 70s to find 33% of cases taking over a year to diagnose 
and 7.5% over 5 years2. 
 
It is well recognised that an important differential diagnosis in IBD is that from Irritable Bowel 
Syndrome (IBS) (or rather IBD is an important differential to exclude in the work up of IBS). 
A literature reporting tests to aid this differentiation has grown over recent years, clearly 
demonstrating that it remains an ongoing challenge without the use of invasive tests3. There 
is however growing evidence of the value of faecal calprotectin in this regard4. At the same 
time there has been interest in the presence of IBS-like symptoms in patients with an 
established diagnosis of IBD. Of particular interest to the subject of this report is a study from 
Canada showing that IBD patients with IBS-like symptoms experience symptoms for longer 
before diagnosis5. 
 
One important mechanism of the delay in IBD diagnosis therefore is likely to be its 
misdiagnosis as IBS. We have therefore set out to examine how prevalent such 
misdiagnosis is in contemporary UK practise.  
 
  
Methods 
 
Design 
A matched case–control study was conducted to determine the differences in prior 
diagnoses of IBS between patients newly diagnosed with IBD and persons without IBD.   
 
Setting 
Data were extracted from the General Practice Research Database downloaded on January 
2011.  These data contain electronic information on consultations, diagnoses and 
prescriptions delivered in primary care in the UK, and have been validated for a wide variety 
of diagnoses including IBD6,7. We used GPRD data from 1987 to October 2010 accessed 
under the University of Nottingham’s GPRD license.  This dataset contains approximately 66 
million person years of available data for analysis among 11.26 million contributing patients 
within 613 general practices. Within the dataset, patients are labelled as ‘acceptable’ for use 
in research if follow up is contiguous and data recorded does not raise worries about validity; 
data is also labelled as up to standard during the period for which an individual practice 
provided continuous data to a high standard defined by GPRD.  
 
Study population 
Incident cases of IBD were identified as acceptable patients with a first recording of IBD after 
the up-to-standard date of their practice or one year after their current registration date, 
whichever date was latest.  The date of this first code for IBD has been previously validated 
as representing the date of diagnosis of IBD8 and is so construed here.    Cases were 
assigned as Crohn’s Disease or ulcerative colitis in a hierarchical fashion accepting that 
where both UC and Crohn’s disease were diagnosed, Crohn’s disease was the correct 
diagnosis.  Cases with only codes for “Inflammatory Bowel Disease” or “Indeterminate 
Colitis” throughout their record were not classified further into Crohn’s or UC but remained 
as a separate category of Indeterminate IBD.   
Controls were selected from all acceptable patients with no record of IBD recording in their 
entire data.  For each case up to 10 controls were selected matched on diagnosis date, 
practice, gender and age (+/- 5 years).  In order to provide a time point from which to assess 
controls, they were assigned the date of diagnosis of their matched case which we 
henceforth refer to as their pseudo-diagnosis date.   
 
Data extracted from GPRD records 
For each subject we assessed age at date of diagnosis / pseudo-diagnosis and categorised 
this into 10 year age bands.  Records for all cases and controls were then examined for the 
presence of a code representing the diagnosis of IBS, and/or codes recording prescription of 
antispasmodic drugs typically used in the treatment of IBS (Mebeverine, Colpermin or 
Alverine Citrate) prior to the date of diagnosis / pseudo-diagnosis. The first date for each of 
these 2 coding options was retained as the first evidence of a consultation for IBS-like 
symptoms in an individual.  
The length of time before diagnosis / pseudo-diagnosis was categorised into 3 month 
intervals for the first year, then yearly intervals up to 10 years prior to diagnosis / pseudo-
diagnosis. 
As potential covariates we extracted data on psychiatric co-morbidity (anxiety or depression) 
and on smoking as we hypothesised that those regarded as typical of patients with IBS 
(young, females with psychiatric co-morbidity)  might be more likely to be misdiagnosed, and 
those with risk factors for Crohn's (smoking) might be more carefully investigated. 
 Statistical analysis 
For all cases of IBD we present the proportion of cases and controls who had IBS recorded 
prior to the date of diagnosis of IBD / pseudo-diagnosis, overall and in the time periods 
specified above.  These analyses are reported both based purely on diagnostic codes for 
IBS, and by using a combination of a diagnosis, and/or a prescription for anti-spasmodics 
typically used in IBS as the diagnostic codes allow more certainty of the GPs opinion that the 
subject had IBS. Finally we limited analysis to those with 10years of follow up and stratified 
by disease type. 
Results are then stratified by gender, by age categorised into 2 groups ( <50years and 50+ 
years of age) and by the date of IBD diagnosis (before or after 1st January 2004 – chosen 
as approximately half of diagnoses are after this date).  In all analyses we present absolute 
numbers of cases, and proportions with 95% confidence intervals. We consider significant 
differences in proportions where confidence intervals are mutually exclusive.  We have then 
calculated both univariate and multivariate odds ratios derived by conditional logistic 
regression considering patients with at least 5 years of follow-up and excluding IBS 
diagnoses (combination of diagnosis and/or prescription) made less than 1 year before 
diagnosis with IBD.  
 
All analyses were conducted in Stata version 11 StataCorp, 4905 Lakeway Drive, 
College Station, Texas 77845 USA. 
 
ETHICAL CONSIDERATIONS 
This study was approved by the Independent Scientific Advisory Committee of the GPRD 
(protocol 11_047).  
Results 
We identified 20,193 incident cases of IBD disease and matched these to 201,393 controls 
who had no evidence of IBD.  Cases were predominantly of Ulcerative Colitis, were almost 
evenly distributed between the sexes (52% female) and were most commonly diagnosed in 
the 4th decade of life (table 1). 
When we examined for the presence of prior diagnoses of IBS, these were almost 3 times as 
common in the IBD patients as in their controls (15.2% versus 5% - P<0.01). Many of these 
excess diagnoses occurred in the year before the diagnosis of IBD (4.4% of cases had a 
new diagnosis of IBS in this time versus 0.4% of controls – P<0.01), however there was a 
highly significant annual excess back as far as 10 years before diagnosis (table 2). 
When the definition of IBS was broadened to include prescriptions for antispasmodic drugs 
as well as diagnostic codes, this accentuated the differences described above suggesting as 
many as 30% of inflammatory bowel disease patients might have been diagnosed or treated 
as having IBS prior to diagnosis compared to 9% of controls.  Again though most marked in 
the year before diagnosis this discrepancy persisted many years before the diagnosis of IBS 
(table 2). Repeating this analysis in only those subjects with at least 10 years of follow up 
yielded similar results (table 3, fig 1). 
 
When similar analyses were conducted only in the subsets of cases with Crohn’s disease or 
with Ulcerative Colitis, the excess of IBS diagnoses between cases and controls was greater 
for Crohn's disease (34.9% ever previously  diagnosed or treated for IBS versus 8.7%)  and 
smaller for UC (25.2% versus 9.2%). This also remained true in the analysis of only subjects 
with 10 years of data (table 4). Otherwise the pattern of results was similar to that for all IBD. 
Stratification by gender showed the absolute but not the relative excess of IBS diagnoses 
was higher in women, with a prior IBS diagnosis or therapy recorded in 35.9% of females 
and 22.8% of males compared to 12.6% of female and 5.3% of male controls. When 
stratified by age the excess of IBS diagnoses was greater in the young, with prior recording 
of IBS or its therapy in 31.3% of those under 50 years of age (compared to 7.8% of their 
controls) and 27.4% of  those over 50 years of age (compared to 10.7% of their controls). 
Our final stratification of the analysis by the date of IBD diagnosis showed that the diagnosis 
and treatment of IBS was more common in both cases and controls in the later period. After 
2004 the absolute increase in IBS before IBD diagnosis was greater but the relative excess 
was smaller (26.7% of cases and 7.4% of controls had such a record before 2004 compared 
to 32.5% of cases and 10.7% of controls after). 
 
When estimating the odds ratio for prior IBS diagnosis among newly diagnosed IBD patients 
and controls, we found the odds ratio for this to be 3.0 [2.8, 3.2] overall. This was higher 
among Crohn's patients (3.6 [3.3, 4.0]]), and lower in UC (2.5 [2.3, 2.8] In our adjusted 
model there was significant statistical interaction between IBD diagnosis and past psychiatric 
history and so we have presented our analysis stratified by this factor, but adjusted for 
smoking (table 5). Overall the increased odds of prior IBS was greater at 3.5 (95% CI 3.1-
3.9) among those without a psychiatric history and slightly lower at 2.4 (2.0-2.9) in those with 
one. 
 
  
Discussion 
We have shown that in UK general practice, patients newly diagnosed with IBD are 
more likely to have a previous diagnosis of IBS than are matched controls. IBD 
patients are in fact 3 times as likely to have a diagnosis or typical therapy for IBS, 
with this occurring in 29.58% of IBD patients and only 9.07% of controls. This excess 
is greater in Crohn's disease than in UC, is greater in the young and in those without 
a previous psychiatric diagnosis, and is greater in absolute but not in relative terms 
in women than in men. The numbers of such diagnoses have not diminished in 
recent years. It is not possible to prove that these diagnoses of IBS represent 
misdiagnoses as we cannot verify retrospectively that IBD was (or was not) present at a time 
before it was actually diagnosed (i.e. around the time of the IBS diagnosis). That IBD was 
present previously is however the most obvious interpretation of our findings. 
Before we accept these findings and their interpretation however we must consider two 
questions. First, is it likely that the association we have found is genuine? And second might 
it be explained by other mechanisms than misdiagnosis? The answer to the first question 
depends upon the opportunities for error and bias in our work. Though the GPRD is known 
to provide diagnoses of high validity6 there is potential for some error in the diagnoses we 
have relied upon.  We should consider therefore whether the specific diagnoses here 
considered (IBS and IBD) are valid. For IBD a validation study has been conducted and 
demonstrates that in excess of 90% of those identified with IBD have good evidence to 
support this7. For IBS no such validation has occurred and in fact the possibility of errors has 
been demonstrated9. In the current study however since our intent is study whether some 
diagnoses of IBS in general practice may be invalid, we do not see the potential for over 
diagnosis of IBS in IBD cases as a weakness, rather it is part of the study design. We do 
however need to be sure that IBS is not under identified in controls. In this regard we are 
reassured by the fact that the 9.07% of controls we found to have records of diagnosis or 
treatment for IBS corresponds quite closely to the prevalence figures found in UK based 
community surveys10,11 (which also found that a large proportion of IBS was not formally 
diagnosed but may still be treated). We must also consider the potential for error in the 
timing of the diagnoses we have used. If the “incident” cases of IBD we have studied were in 
truth prevalent, then the diagnosis of IBS may not predate them. We believe that this is 
unlikely to be a major problem however based upon the previous demonstration by Lewis 
and colleagues12 of the validity of the algorithm for identifying incident cases which we have 
used.  
We must also consider the possibilities of bias. Since the cases and controls were selected 
in an unbiased manner and their data collected prospectively for reasons unrelated to the 
study, neither selection nor recall bias should have occurred. It is however possible that an 
ascertainment bias might act if patients with IBS by dint of receiving more medical attention 
to gastrointestinal symptoms were rendered more likely to have IBD diagnosed. Since the 
greatest effect of such a mechanism would be likely to occur around the time of the initial 
diagnostic work up of a patient this might well at least in part explain the excess of IBS 
diagnoses in the year before IBD diagnosis, however it is harder to conceive of how such a 
bias would act at earlier time points. Another potential bias in our analysis is due to the fact 
that we have not limited all analyses to patients with follow up throughout the time period 
studied. However, when we included only cases and controls who had at least 10 years of 
follow up data and repeated our analyses in this restricted group (Table 3 and fig 1c) the 
larger apparent excess of IBS diagnoses in this analysis suggests that if anything such a 
bias is causing us to underestimate the true size of the problem we are studying. 
 
Also relevant to the assessment of the validity of our work is the manner in which it fits with 
pre-existing knowledge of the relationship we have studied. Over recent years there has 
been much interest in IBS symptoms in those already diagnosed with IBD and some interest  
in these symptoms prior to diagnosis, but surprisingly little has been published directly 
relevant to prior IBS diagnoses. What we do know is that when previously formally studied, 
there was a marked delay in the diagnosis of IBD in the UK2. This is reflected also in 
Canadian data which suggest that delays are greater in those with IBS-like symptoms, and 
which found that 33% of patients had a prior diagnosis of IBS at the time of IBD diagnosis 
(closely mirroring our own figures)5. In contrast to our results however this group found that 
delays were greater in the old (while we found that IBS diagnoses were more common in the 
young). Far more is published upon the presence of IBS symptoms within those already 
diagnosed with IBD. There can be no doubt from this literature that IBS symptoms are often 
present in those with IBD, being present in remission in about a third of patients in a number 
of studies13,14. In one study the proportion of patients so affected is even higher than the 
proportion we found to have been previously diagnosed with IBS, with 46% of UC patients in 
remission having IBS like symptoms in a study from Tehran15. 
 
Considering the above, we believe that our methodology is sound and our results coherent 
with the existing literature. We must then consider what mechanisms other than 
misdiagnosis might produce this result. It has previously been questioned whether  IBS 
symptoms prior to IBD diagnosis represent a prodrome16 with presumably the implication 
that the disease is not fully present at this time and might not be diagnosable. Since GI 
inflammation in various sites has been associated with a number of subgroups of IBS 17,18,19, 
one might hypothesise that a proportion of these cases are passing through a mild to a more 
severe inflammation in some cases as a stage in the evolution of IBD. Equally if the 
frequency of IBS in IBD patients in remission is increased due to shared risk factors (of 
which we are as yet unaware) rather than to a direct effect of the inflammatory damage from 
IBD, then one might expect increased IBS prior to IBD developing also (in effect this would 
suggest the association is explained by residual unknown confounders). The counterpoint to 
these arguments is of course the suggestion that many of the IBS symptoms in IBD may be 
due to clinically occult disease activity20. 
 
 If we accept that the excess IBS diagnoses we have described do represent incorrect 
diagnoses and diagnostic delays our results suggest that about 10%of IBD patients receive 
an incorrect diagnosis of IBS prior to receiving their diagnosis of IBD. Roughly one third of 
these incorrect diagnoses occur in the year before a final diagnosis is made (and probably 
therefore during the investigation leading to the diagnosis of IBD), but the rest occur earlier, 
and a small subgroup (3% of all eventual IBD diagnoses) attract an erroneous diagnosis of 
IBS for their symptoms 5 or more years before the eventual identification of IBD as the 
cause of their problems. If GPs using Mebeverine, Colpermin and Alverine Citrate do so 
because they believe that they are treating IBS, then the frequency of these delays to 
diagnosis may be even greater, with combined figures for IBS diagnosis or these therapies 
suggesting this may occur in as many as 22% of all eventual IBD diagnoses and persist for 
more than a year in 12% and for over 5 years in 6%.Recent guidance from the National 
Institute for Health and Clinical Excellence (NICE)21, and from the American College of 
Gastroenterology (ACG)22 on the diagnosis and management of IBS has recommended that 
in people who meet the IBS diagnostic criteria antibody testing should be undertaken to 
exclude coeliac disease.  To exclude IBD in the young without alarm symptoms or family 
history however, the ACG does not recommend tests, and NICE recommends only a full 
blood count, ESR and CRP. CRP is of course at best an imperfect test, and can be clearly 
outperformed by faecal calprotectin4. Given that approaching 1% of UK IBS diagnoses will 
be followed by a diagnosis of IBD within 4 years, and that based on UK costs at least there 
is evidence that screening IBS patients for IBD using faecal calprotectin is more cost 
effective than current practice in the UK23, we believe that this test should be routinely used. 
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Case Control 
n(%) n(%) 
N=20 193 201 393 
Gender     
Male 9743 (48) 97 159 (48) 
Female 10 450 (52) 104 234 (52) 
      
Age (years)     
0-9 156 (0.8) 2225 (1.1) 
10-19 1405 (7.0) 14 532 (7.2) 
20-29 2883 (14.3) 26 935 (13.4) 
30-39 3478 (17.2) 34 856 (17.3) 
40-49 3256 (16.1) 33 268 (16.5) 
50-59 3082 (15.3) 31 021 (15.4) 
60-69 2818 (14.0) 27 880 (13.8) 
70-79 2114 (10.5) 21 076 (10.5) 
80-89 911 (4.5) 8834 (4.4) 
90+ 87 (0.4) 766 (0.4) 
      
UC 10 679 (52.9)  
Crohns 7435 (36.8)  
Indeterminate IBD 2079 (10.3)  
Psychiatric condition  5085 (25.2) 42990 (21.4) 
Ever smoker  10 152 (50.3) 87 538 (43.5) 
Median follow-up (years) 
[Interquartile Range] 5.23 [2.13, 9.28]  5.22 [2.15, 9.27]  
 
Table 1. Demographic characteristics of cases and controls. 
 
 
   
Prior 
diagnosis of 
IBS 
Case       Control       
    N=20,193 %     CIs N=201,393 % CIs 
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Ever 3,067 15.19 14.69 15.68 10,124 5.03 4.93 5.12 
Never 17,126 84.81 84.32 85.31 191,269 94.97 94.88 95.07 
                  
0-3 months 329 1.63 1.45 1.80 220 0.11 0.09 0.12 
3-6 months 240 1.19 1.04 1.34 212 0.11 0.09 0.12 
6-9 months 172 0.85 0.73 0.98 227 0.11 0.10 0.13 
9-12 months 142 0.70 0.59 0.82 203 0.10 0.09 0.11 
1-2 years 337 1.67 1.49 1.85 852 0.42 0.39 0.45 
2-3 years 253 1.25 1.10 1.41 790 0.39 0.36 0.42 
3-4 years 193 0.96 0.82 1.09 743 0.34 0.40 0.40 
4-5 years 196 0.97 0.84 1.11 718 0.36 0.33 0.38 
5-6 years 135 0.67 0.56 0.78 697 0.37 0.33 0.38 
6-7 years 148 0.73 0.62 0.85 606 0.30 0.28 0.32 
7-8 years 102 0.51 0.41 0.60 553 0.27 0.25 0.30 
8-9 years 93 0.46 0.37 0.55 542 0.27 0.25 0.29 
9-10 years 101 0.50 0.40 0.60 485 0.24 0.22 0.26 
10+ years 626 3.10 2.86 3.34 3276 1.63 1.57 1.68 
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Ever 5,974 29.58 28.95 30.21 183,117 9.07 8.95 9.20 
Never 14,219 70.42 69.79 71.05 18,276 90.93 90.80 91.05 
                  
0-3 months 1,051 5.20 4.90 5.51 530 0.26 0.24 0.29 
3-6 months 596 2.95 2.72 3.18 532 0.26 0.24 0.29 
6-9 months 394 1.95 1.76 2.14 522 0.26 0.24 0.28 
9-12 months 324 1.60 1.43 1.78 481 0.24 0.22 0.26 
1-2 years 727 3.60 3.34 3.86 1,933 0.96 0.92 1.00 
2-3 years 510 2.53 2.31 2.74 1,733 0.86 0.82 0.90 
3-4 years 370 1.83 1.65 2.02 1,573 0.78 0.74 0.82 
4-5 years 329 1.63 1.45 1.80 1,524 0.76 0.72 0.79 
5-6 years 261 1.29 1.14 1.45 1,408 0.70 0.66 0.74 
6-7 years 244 1.21 1.06 1.36 1,214 0.60 0.57 0.64 
7-8 years 209 1.04 0.90 1.17 1,036 0.51 0.48 0.55 
8-9 years 171 0.85 0.72 0.97 975 0.48 0.45 0.51 
9-10 years 145 0.72 0.60 0.83 829 0.41 0.38 0.44 
10+ years 643 3.18 2.94 3.43 3,986 1.98 1.92 2.04 
Table 2. Prior identification of IBS (through diagnostic codes only or diagnostic and 
therapeutic codes) for cases of inflammatory bowel disease and their matched 
controls. 
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    N=4,380 % 95% CIs N=43,334 % 95% CIs 
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Ever 1530 34.9 33.5, 36.3 5653 13.0 12.7,13.4 
Never 2850 65.1 63.7, 66.5 37681 87.0 86.6,87.3 
            
0-3 
months 
214 4.9 4.2,5.5 79 0.2 0.1,0.2 
3-6 
months 
124 2.8 2.3,3.3 103 0.2 0.2,0.3 
6-9 
months 
61 1.4 1.0,1.7 93 0.2 0.2,0.3 
9-12 
months 
60 1.4 1.0,1.7 93 0.2 0.2,0.3 
1-2 years 137 3.1 2.6,3.6 368 0.8 0.8,0.9 
2-3 years 97 2.2 1.8,2.6 374 0.9 0.8,1.0 
3-4 years 90 2.0 1.6,2.5 374 0.9 0.8,1.0 
4-5 years 76 1.7 1.3,2.1 384 0.9 0.8,1.0 
5-6 years 73 1.7 1.3,2.1 378 0.9 0.8,1.0 
6-7 years 75 1.7 1.3,2.1 363 0.8 0.8,0.9 
7-8 years 69 1.6 1.2,1.9 321 0.7 0.7,0.8 
8-9 years 70 1.6 1.2,2.0 392 0.9 0.8,1.0 
9-10 
years 
61 1.4 1.0,1.7 326 0.7 0.7,0.8 
10+ years 323 7.4 6.6,8.1 2005 4.6 4.4,4.8 
 
Table 3 Prior identification of IBS (diagnostic or therapeutic codes) for cases of 
inflammatory bowel disease and their matched controls with at least 10 years of 
follow up.  
   
Prior diagnosis 
of IBS 
Crohn’s disease control UC control 
    
N=1551 % 95% CIs N=15,07
2 
% 95% CIs N=2327 % 95% CIs N=22997 % 95% CIs 
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Ever 622 40.1 37.7,42.5 1,914 12.7 12.2,13.2 704 30.3 28.4,32.1 3018 13.1 12.7,13.6 
Never 929 59.9 57.5, 62.3 13,158 87.3 86.8,87.8 1623 69.7 67.9,71.6 19979 86.9 86.4,87.3 
              
0-3 months 93 6.0 4.8,7.2 31 0.2 0.1,0.3 93 4.0 3.2,4.8 35 0.2 0.1,0.2 
3-6 months 65 4.2 3.2,5.2 31 0.2 0.1,0.3 52 2.2 1.6,2.8 60 0.3 0.2,0.3 
6-9 months 27 1.7 1.1,2.4 40 0.3 0.2,0.3 27 1.2 0.7,1.6 43 0.2 0.1,0.2 
9-12 months 27 1.7 1.1,2.4 37 0.2 0.2,0.3 27 1.2 0.7,1.6 46 0.2 0.1,0.2 
1-2 years 66 4.3 3.3,5.3 133 0.9 0.7,1.0 53 2.3 1.7,2.9 185 0.8 0.7,0.9 
2-3 years 36 2.3 1.6,3.1 121 0.8 0.7,0.9 49 2.1 1.5,2.7 205 0.9 0.8,1.0 
3-4 years 28 1.8 1.1,2.5 139 0.9 0.7,1.0 49 2.1 1.5,2.7 188 0.8 0.7,0.9 
4-5 years 31 2.0 1.3,2.7 130 0.9 0.7,1.0 31 1.3 0.9,1.8 203 0.9 0.8,1.0 
5-6 years 31 2.0 1.3,2.7 132 0.9 0.7,1.0 31 1.3 0.9,1.8 212 0.9 0.8,1.0 
6-7 years 35 2.3 1.5,3.0 125 0.8 0.7,1.0 32 1.4 0.9,1.8 190 0.8 0.7,0.9 
7-8 years 26 1.7 1.0,2.3 105 0.7 0.6,0.8 32 1.4 0.9,1.8 179 0.8 0.7,0.9 
8-9 years 17 1.1 0.6,1.6 125 0.8 0.7,1.0 43 1.9 1.3,2.4 217 0.9 0.8,1.1 
9-10 years 25 1.6 1.0,2.2 109 0.7 0.6,0.9 28 1.2 0.8,1.6 175 0.8 0.6,0.9 
10+ years 115 7.4 6.1,8.7 656 4.4 4.0,4.7 157 6.8 5.8,7.8 1080 4.7 4.4, 5.0 
 
Table 4: Prior identification of IBS (diagnostic or therapeutic codes) for cases of Crohn's disease and UC and their matched controls 
with at least 10 years of follow up.  
  With psychiatric 
diagnosis 
Without psychiatric 
diagnosis 
(number of 
observations) 
All IBD    
Diagnosis of IBS 2.4 [2.0, 2.9] 3.5 [3.1, 3.9] (8480) 
Smoking 1.2 [1.1, 1.4] 1.4 [1.3, 1.5] (42856) 
Crohns    
Diagnosis of IBS 2.3 [1.7, 3.3] 4.3 [3.6, 5.3] (3055) 
Smoking 1.4 [1.1, 1.8] 1.6 [1.4, 1.8] (15160) 
UC    
Diagnosis of IBS 2.2 [1.7, 3.0] 2.9 [2.5, 3.4] (4270) 
Smoking 1.2 [1.0, 1.4] 1.3 [1.2, 1.4] (23588) 
 
 
Table 5. Odds ratios for prior IBS diagnosis of or treatment for >/= 1 year before diagnosis 
with IBD  for subjects with at least 5 years of follow-up stratified by psychiatric history and 
mutually adjusted for smoking history. 
Figure Legends 
 
Fig1: Proportion of cases and controls with prior diagnosis of IBS (diagnostic and therapeutic 
codes) in those with at least 10 years of follow up 
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